Lilly completes the retatrutide data package and plans a 2027 filing

Eli Lilly said on August 5, 2026 that the clinical data package for retatrutide, its experimental triple-hormone weight-loss injection, is now complete, and that it plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first quarter of 2027. The filing would cover obesity, obstructive sleep apnea and knee osteoarthritis pain. ^[2]

The announcement came inside Lilly's second-quarter earnings report, not as a standalone data release. ^[1][2] Chair and CEO David A. Ricks described retatrutide as the company's "next-generation weight-loss medicine" with "its complete clinical data package in hand." ^[2]

What the trials showed

The completed package followed positive topline results from two more Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, reported on July 23, 2026. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% of body weight at 80 weeks. In TRIUMPH-2, participants with type 2 diabetes lost up to 20.8% at the same timepoint. ^[1] Lilly's earnings summary said positive data came from three additional Phase 3 obesity trials during the period. ^[2]

Those percentages are top-line figures from company announcements. Full trial details — including side effect rates, dropout rates and how many people reached the highest doses — were not in the sources reviewed here. Retatrutide targets three hormone receptors, unlike semaglutide (Ozempic, Wegovy, Rybelsus), which targets one, and tirzepatide (Mounjaro, Zepbound), which targets two. Cross-trial comparisons are not reliable because study lengths, patient groups and analysis methods differ.

The fight over "biologic"

Lilly says it intends to file a Biologics License Application rather than a New Drug Application, but the classification is tied up in unresolved litigation with the FDA. ^[1] The agency determined that retatrutide is neither a protein nor a biological product. A district court vacated that designation but sent the broader question back to the agency, and Lilly has appealed. ^[1]

The stakes are about market protection. A biologic carries 12 years of exclusivity; a conventional drug application carries five. ^[1] That difference determines how many years pass before other companies can try to sell competing versions.

Lilly's obesity franchise is already large. Second-quarter 2026 revenue rose 48% to $23.0 billion, with worldwide Mounjaro sales of $9.9 billion and U.S. Zepbound sales of $4.9 billion. ^[2] Lilly also noted that U.S. realized prices fell, partly because of previously announced cash-pay price reductions for Zepbound. ^[2]

Why it matters for patients

Retatrutide is still investigational. It is not approved anywhere, and a first-quarter 2027 filing means FDA review would run well beyond that date. When an approval decision might come is not stated in the sources.

The three proposed indications matter because they go beyond weight alone. Obstructive sleep apnea and knee osteoarthritis pain are conditions that insurers sometimes cover more readily than obesity itself, and tirzepatide already has a sleep apnea indication path in the broader market. Whether retatrutide's label would include all three is up to the FDA.

The exclusivity fight is less visible to patients but affects long-term cost. Twelve years versus five years of protection changes when lower-priced competition could arrive — though in practice, biosimilar and generic entry depends on patents as well as regulatory exclusivity, which the sources do not detail.

One immediate safety issue: because retatrutide is not approved, any product sold as retatrutide today is unapproved. Lilly has brought six U.S. lawsuits against sellers of unapproved retatrutide. ^[1] Nothing in the sources suggests such products have been tested for purity, dose accuracy or sterility.

What happens next

• September 24, 2026: The Seventh Circuit hears oral arguments in Lilly's appeal against the FDA. The outcome determines which application type retatrutide can use and how long its exclusivity would run. ^[1]
• Before the end of 2026: Further readouts from the TRIUMPH program are expected. ^[1]
• First quarter of 2027: Lilly's planned FDA submission. ^[2]

Separately, Lilly submitted orforglipron (Foundayo), its oral GLP-1, for type 2 diabetes in the U.S. during the quarter; the FDA approved it for obesity in April 2026. ^[2][1]